Shao Guoliang, Zou Yinghua, Lucatelli Pierleone, Tsilimigras Diamantis I, Shimise Shigeo, Kawaguchi Takumi
Department of Intervention, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China.
Ann Transl Med. 2021 Apr;9(8):714. doi: 10.21037/atm-21-1678.
Liver cancer is among the 10 most common tumors globally. In China, liver cancer ranks 4 for prevalence and 3 for mortality among all malignant tumors. With respect to the treatment of primary liver cancer, there are a number of therapies currently available, including surgical resection, liver transplantation, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, radiation therapy, targeted drug therapy and immunotherapy. Clinical practice and research have shown that, compared with conventional TACE (cTACE), drug-eluting bead TACE (DEB-TACE) can achieve a higher response rate and longer survival time in patients with primary liver cancer. Compared with that of cTACE, DEB-TACE has more favorable basic conditions for achieving uniformity, which could facilitate the standardization of operation techniques. China is the country with the highest incidence of primary liver cancer, accounting for more than 50% of the global patients, and its etiology and epidemiology in Chinese patients differ from those in Europeans and Americans. Therefore, experts in China have drafted these technical recommendations for the standard operation of drug-eluting beads for the treatment of liver cancer on the basis of accumulated abundant clinical experience and evidence-based medical data.
肝癌是全球十大常见肿瘤之一。在中国，肝癌在所有恶性肿瘤中的发病率排名第4，死亡率排名第3。关于原发性肝癌的治疗，目前有多种治疗方法，包括手术切除、肝移植、消融、经动脉化疗栓塞术（TACE）、全身化疗、放射治疗、靶向药物治疗和免疫治疗。临床实践和研究表明，与传统TACE（cTACE）相比，载药微球TACE（DEB-TACE）在原发性肝癌患者中可实现更高的缓解率和更长的生存时间。与cTACE相比，DEB-TACE在实现均匀性方面具有更有利的基础条件，这有助于手术技术的标准化。中国是原发性肝癌发病率最高的国家，占全球患者的50%以上，其病因和流行病学在中国患者与欧美患者中有所不同。因此，中国专家在积累了丰富临床经验和循证医学数据的基础上，起草了这些肝癌治疗载药微球标准操作的技术建议。
